Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PRELI domain containing 3B pseudogene 10 (PRELID3BP10) is a human pseudogene, meaning it is a genomic DNA sequence similar to a known gene but generally nonfunctional due to mutations that disrupt coding or regulatory regions. Pseudogenes typically do not code for functional proteins, and PRELID3BP10 does not appear to be transcribed or translated into a biologically active product, nor is it associated with disease pathology, molecular targeting, or drug response in current scientific databases and publications. It is not a member of any therapeutic target class, such as receptor, enzyme, transporter, transcription factor, or ion channel. There are no references in GWAS, molecular function, or disease association databases indicating a role for PRELID3BP10 in human disease or therapy. Therefore, it should not be considered a valid therapeutic target or biomarker based on current knowledge. If you need structured data extraction, PRELID3BP10 would typically be excluded from lists of actionable drug targets and may require annotation as a pseudogene rather than a valid molecular target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on PRELI domain containing 3B pseudogene 10 (PRELID3BP10).